Premium
Suppressing the growth of rectal cancer xenografts derived from patient tumors by an adenovector expressing small hairpin RNA targeting Bcl‐XL
Author(s) -
Zhu Hongbo,
Zhou Wei,
Hu Jingzi,
Huang Zhongting,
Lao Weifeng,
Huang Xuefeng,
He Chao
Publication year - 2012
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.2681
Subject(s) - small hairpin rna , colorectal cancer , bcl xl , apoptosis , cancer research , cancer , medicine , biology , programmed cell death , gene knockdown , biochemistry
Abstract Background Bcl‐XL, a mitochondria membrane protein, is overexpressed in colorectal cancers and promotes cell survival. We have previously shown that the adenovector expressing small hairpin (sh)RNA targeting Bcl‐XL could induce significantly apoptosis in colon cancer cells. In the present study, we aimed to further detect the anti‐cancer effect of adenovector expressing the shRNA targeting Bcl‐XL (Ad/Bcl‐XL shRNA) on rectal cancer xenografts that were derived from patient tumors. Methods We first established three rectal cancer xenografts. These xenografts were subsequently treated with Ad/Bcl‐XL shRNA alone or in combination with 5‐fluouracil (5‐Fu). Finally, the inhibition of tumor growth, survival time and induction of apoptosis were analyzed. Results The results obtained demonstrated that Ad/Bcl‐XL shRNA could effectively suppress the tumor growth of all three rectal cancer xenografts and prolong their survival time. After being combined with 5‐Fu, the suppressing effect of Ad/Bcl‐XL shRNA was enhanced further. In addition, the data also showed that Ad/Bcl‐XL shRNA combined with 5‐Fu could significantly increase the apoptotic ratio in the rectal cancer xenograft. Conclusions These data indicate that Ad/Bcl‐XL shRNA with or without 5‐Fu has effective anti‐tumor effects on the patient tumor‐derived rectal cancer xenografts, suggesting that it could be a potential strategy for rectal cancer therapy. Copyright © 2012 John Wiley & Sons, Ltd.